Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: Estimates from Saskatchewan health data

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  Migliaccio Walle, Kristen ^a   Stokes, Michael ^b   Proskorovsky, Irina ^b   Popovici Toma, Dan ^c   El Hadi, Wissam ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNITED BIOSOURCE CORPORATION   (Canada)

^c SANOFI   (France)

^d Bristol Myers Squibb Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BLEEDING; CANADA; DIABETES MELLITUS; DIFFUSE VASCULAR DISEASE; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STROKE; SURVIVAL TIME; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; AGED; COMORBIDITY; COMPARATIVE STUDY; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; RISK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; RISK; SASKATCHEWAN; STROKE; TREATMENT OUTCOME;

EID: 77956816394     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-40     Document Type: Article

References (18)

1. Canadian Cardiovascular Society 2005 Peripheral Artery Disease Consensus Document. , http://www.ccs.ca/download/consensus_conference/consensus_conference_archives/CCFinalPre_CJC_Pub.pdf
2. Shamoun F, Sural N, Abela G. Peripheral artery disease: therapeutic advances. Expert Rev Cardiovasc Ther 2008, 6:539-553. 10.1586/14779072.6.4.539, 18402543.
3. Froehlich JB, Mukherjee D, Avezum A, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006, 151:1123-1238. 10.1016/j.ahj.2005.11.005, 16644349.
4. Anand RG, Ventura HO, Mehra MR. Is heart failure more prevalent in patients with peripheral arterial disease? A meta-analysis. Congest Heart Fail 2007, 13:319-322. 10.1111/j.1527-5299.2007.07344.x, 18046089.
5. O'hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006, 113:388-393. 10.1161/CIRCULATIONAHA.105.570903, 16432070.
6. Spencer FA, Lessard D, Doubeni C, et al. Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting. Am Heart J 2007, 153:140-146. 10.1016/j.ahj.2006.09.009, 17174652.
7. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public and physician awareness of peripheral artery disease. J Vasc Interv Radiol 2002, 13:7-11. 10.1016/S1051-0443(07)60002-5, 11788688.
8. Selvin E, Erlinger TP. Prevalence and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743. 10.1161/01.CIR.0000137913.26087.F0, 15262830.
9. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary care. JAMA 2001, 286:1317-1324. 10.1001/jama.286.11.1317, 11560536.
10. Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 2003, 145:622-627. 10.1067/mhj.2003.6, 12679757.
11. Watson K, Watson BD, Pater KS. Peripheral arterial disease: a review of disease awareness and management. Am J Geriatr Pharmacother 2006, 4:365-379. 10.1016/j.amjopharm.2006.12.006, 17296541.
12. Malcolm E, Downey W, Strand LM, et al. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Marketing Surveillance 1993, 6:175-264.
13. Ontario Case Costing Initiative. OCCI Costing Analysis Tool. , http://www.occp.com
14. Caro JJ, Migliaccio-Walle K, Ishak KJ, et al. The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada. BMC Health Serv Res 2006, 6:99. 10.1186/1472-6963-6-99, 1564006, 16907982.
15. Margolis J, Barron JJ, Grochulski WD. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005, 11:727-734.
16. Efron B, Tibshirani RJ. An Introduction to the Bootstrap 1993, New York: Chapman & Hall.
17. Spencer F, Lessard D, Doubeni C, Yarzebski J, Gore JM, Goldberg RJ. Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting. Am Heart J 2007, 153:140-146. 10.1016/j.ahj.2006.09.009, 17174652.
18. Bell A, Hill MD, Herman RJ, et al. Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol 2009, 25:345-351. 2722477, 19536375.